Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical company Acusphere has reported that its Imagify Perfusion Stress Echo agent, which is used for evaluating chest pain patients at risk of heart attack, has been found to be effective and well-tolerated in a number of international multi-center phase III clinical trials.
Subscribe to our email newsletter
According to data presented at the American Heart Association’s Scientific Sessions, when compared to nuclear stress – the most frequently used imaging procedure for the assessment of coronary heart disease – Imagify was shown to be just as good at determining whether or not a patient is suffering from the disease. It was also shown to be superior in ruling out disease in patients with a lower prevalence of disease and superior in detecting disease in patients with a higher prevalence of disease.
Roxy Senior, director of echocardiology at the Northwick Park Hospital and the lead investigator in Phase III trials, said: “These Phase III data add to the growing body of efficacy and safety data on Imagify, which has now been evaluated in more than 1,000 patients, and further indicates that Imagify is an excellent perfusion imaging agent, superior to standard stress echocardiography since it enables perfusion to be assessed, and just as accurate as nuclear stress testing.”